Table 3.

Diagnostic performance of model in MPN patients with different clinical characteristic

Group	n	Se (%)	Sp (%)	+LR	-LR	PPV (%)	NPV (%)	YI	Accuracy (%)
All stage MPN vs. BPN	60	68.3	84.5	4.406	0.375	0.82	0.721	0.528	76.3
Early MPN vs. BPN	26	42.3	84.5	2.729	0.682	0.55	0.766	0.268	71.4
Advanced MPN vs. BPN	31	87.1	84.5	5.619	0.153	0.75	0.924	0.716	85.4
LM(-) MPN vs. BPN	20	35.0	84.5	2.258	0.769	0.44	0.790	0.195	71.8
LM(+) MPN vs. BPN	24	87.5	84.5	5.645	0.148	0.70	0.942	0.720	85.4
DM(-) MPN vs. BPN	27	44.4	84.5	2.865	0.658	0.57	0.766	0.289	71.7
DM(+) MPN vs. BPN	18	94.4	84.5	6.091	0.066	0.65	0.980	0.789	86.8
≥3cm MPN vs. BPN	43	94.1	84.5	6.071	0.070	0.82	0.942	0.786	88.1
<3cm MPN vs. BPN	17	58.1	84.5	3.748	0.496	0.52	0.875	0.426	78.7

MPN malignant pulmonary nodule, BPN benign pulmonary nodule, Se sensitivity, Sp specificity, AUC area under curve, 95%CI 95% confidence interval, +LR positive likelihood ratio, -LR negative likelihood ratio, PPV positive predictive value, NPV negative predictive value, YI Youden’s index, Advanced advanced LC, LM(-) Lymph node metastasis negative, LM(+) Lymph node metastasis positive, DM(-) distant metastasis negative, DM(+) distant metastasis positive, <3cm diameter<3cm, ≥3cm diameter≥3cm